EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 3.0

Can We Slow Down Biological Age Progression? Study Protocol for the proBNPage Reduction (PBAR) Randomized, Double-Blind, Placebo-Controlled Trial (Effects of 4 “Anti-Aging” Food Supplements in Healthy Older Adults)

Antonio Muscari iD, Paola Forti, Mara Brizi, Donatella Magalotti, Eleonora Capelli, Simona Potì, Filomena Piro, Paolo Pandolfi, Vincenza Perlangeli, Eric Ramazzotti, Giovanni Barbara, PBAR Study Group

Clinical Interventions in Aging · 2023

DOI: 10.2147/cia.s422371 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Clinical Interventions in Aging, 2023. Verfasst von Antonio Muscari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Quality of Life, Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The availability of a simple and reliable marker of biological age might allow an acceleration of the research in the field of longevity extension. Previous studies suggest that this marker might be the N-terminal of B-type natriuretic peptide precursor (NT-proBNP), from which proBNPage, a biological age surrogate, can be calculated. Objectives of the study: 1) To fine-tune the method of proBNPage progression assessment and 2) To establish whether 4 "anti-aging" treatments, which provided promising results in previous studies, can modify proBNPage progression. Patients and Methods: This is a double-blind randomized placebo-controlled clinical trial on 120 adults aged 65-80 years, free of cardiovascular diseases. Participants will be randomized into 3 groups: A) Coenzyme Q10 100 mg bid + Selenium 100 mcg; B) Resveratrol 350 mg bid + TA-65 (Astragalus Membranaceus extract) 100U; C) Placebo-1 bid + Placebo-2. They will be followed for 2 years and checked 8 times, to assess both proBNPage progression and treatment safety. Secondary variables (handgrip strength, aerobic capacity at the step test and quality of life) will also be assessed. Primary outcome will be the demonstration of significant changes of proBNPage, compared to baseline, in the 3 groups at 6, 12, 18 and 24 months. Secondary outcome will be the demonstration of similar changes of secondary variables. Statistical analyses will be mainly performed by repeated measures ANOVA (both according to intention to treat and per protocol) and paired t tests. The study was approved by the Ethics Committee Area Vasta Emilia Centro, Emilia-Romagna Region, ID: 64/2022/Sper/AOUBo.

Trial registration

ClinicalTrials.gov, NCT05500742.

Conclusion

The use of proBNPage as a surrogate of biological age may prove an easy method to select anti-aging treatments worthy of further, more complex assessments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeCardiovascular DiseasesHumansAgedHand StrengthDietary SupplementsAgingDouble-Blind MethodTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

NT-proBNPanti-aging treatmentsbiological agefood supplementslongevityrandomized clinical trialstudy protocol

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Medical-Surgical Department of Digestive, Hepatic and Endocrine-Metabolic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Pharmaceutical Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Epidemiological and Health Promotion Unit, Department of Public Health, AUSL Bologna, Bologna, Italy.
  • LUM Metropolitan Laboratory, AUSL Bologna, Bologna, Italy.

ORCID-Profile: Antonio Muscari

Zitieren

APA

Muscari, A., Forti, P., Brizi, M., Magalotti, D., Capelli, E., Potì, S., Piro, F., Pandolfi, P., Perlangeli, V., Ramazzotti, E., Barbara, G., & PBAR Study Group (2023). Can We Slow Down Biological Age Progression? Study Protocol for the proBNPage Reduction (PBAR) Randomized, Double-Blind, Placebo-Controlled Trial (Effects of 4 “Anti-Aging” Food Supplements in Healthy Older Adults). Clinical Interventions in Aging. https://doi.org/10.2147/cia.s422371

Vancouver

Muscari A, Forti P, Brizi M, Magalotti D, Capelli E, Potì S, et al. Can We Slow Down Biological Age Progression? Study Protocol for the proBNPage Reduction (PBAR) Randomized, Double-Blind, Placebo-Controlled Trial (Effects of 4 “Anti-Aging” Food Supplements in Healthy Older Adults). Clinical Interventions in Aging. 2023. doi:10.2147/cia.s422371

BibTeX
@article{Muscari2023,
  author = {Muscari, Antonio and Forti, Paola and Brizi, Mara and Magalotti, Donatella and Capelli, Eleonora and Potì, Simona and Piro, Filomena and Pandolfi, Paolo and Perlangeli, Vincenza and Ramazzotti, Eric and Barbara, Giovanni and PBAR Study Group, PBAR Study Group},
  title = {Can We Slow Down Biological Age Progression? Study Protocol for the proBNPage Reduction (PBAR) Randomized, Double-Blind, Placebo-Controlled Trial (Effects of 4 “Anti-Aging” Food Supplements in Healthy Older Adults)},
  journal = {Clinical Interventions in Aging},
  year = {2023},
  doi = {10.2147/cia.s422371}
}
Kostenlos starten →